{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T11:27:07Z","timestamp":1791977227625,"version":"4.4.0"},"reference-count":85,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,8,19]],"date-time":"2021-08-19T00:00:00Z","timestamp":1629331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Aging Neurosci."],"abstract":"<jats:p>Down syndrome (DS) is the primary genetic cause of intellectual disability (ID), which is due to the triplication of human chromosome 21 (HSA21). In addition to ID, HSA21 trisomy results in a number of neurological and physiological pathologies in individuals with DS, including progressive cognitive dysfunction and learning and memory deficits which worsen with age. Further exacerbating neurological dysfunction associated with DS is the concomitant basal forebrain cholinergic neuron (BFCN) degeneration and onset of Alzheimer\u2019s disease (AD) pathology in early mid-life. Recent single population RNA sequencing (RNA-seq) analysis in the Ts65Dn mouse model of DS, specifically the medial septal cholinergic neurons of the basal forebrain (BF), revealed the mitochondrial oxidative phosphorylation pathway was significantly impacted, with a large subset of genes within this pathway being downregulated. We further queried oxidative phosphorylation pathway dysregulation in Ts65Dn mice by examining genes and encoded proteins within brain regions comprising the basocortical system at the start of BFCN degeneration (6 months of age). In select Ts65Dn mice we demonstrate significant deficits in gene and\/or encoded protein levels of Complex I-V of the mitochondrial oxidative phosphorylation pathway in the BF. In the frontal cortex (Fr Ctx) these complexes had concomitant alterations in select gene expression but not of the proteins queried from Complex I-V, suggesting that defects at this time point in the BF are more severe and occur prior to cortical dysfunction within the basocortical circuit. We propose dysregulation within mitochondrial oxidative phosphorylation complexes is an early marker of cognitive decline onset and specifically linked to BFCN degeneration that may propagate pathology throughout cortical memory and executive function circuits in DS and AD.<\/jats:p>","DOI":"10.3389\/fnagi.2021.707950","type":"journal-article","created":{"date-parts":[[2021,8,19]],"date-time":"2021-08-19T11:29:50Z","timestamp":1629372590000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":33,"title":["Oxidative Phosphorylation Is Dysregulated Within the Basocortical Circuit in a 6-month old Mouse Model of Down Syndrome and Alzheimer\u2019s Disease"],"prefix":"10.3389","volume":"13","author":[{"given":"Melissa J.","family":"Alldred","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Han","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace E.","family":"Stutzmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen D.","family":"Ginsberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,8,19]]},"reference":[{"key":"B1","first-page":"1","article-title":"Guide to performing relative quantitation of gene expression using real-time quantitative PCR","volume-title":"Applied Biosystems Product Guide","year":"2004"},{"key":"B2","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.neurobiolaging.2017.05.002","article-title":"Age exacerbates abnormal protein expression in a mouse model of down syndrome","volume":"57","author":"Ahmed","year":"2017","journal-title":"Neurobiol. Aging"},{"key":"B3","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1002\/hipo.22832","article-title":"CA1 pyramidal neuron gene expression mosaics in the Ts65Dn murine model of down syndrome and Alzheimer\u2019s disease following maternal choline supplementation","volume":"28","author":"Alldred","year":"2018","journal-title":"Hippocampus"},{"key":"B4","doi-asserted-by":"publisher","first-page":"9871","DOI":"10.1096\/fj.201802669RR","article-title":"Long-term effects of maternal choline supplementation on CA1 pyramidal neuron gene expression in the Ts65Dn mouse model of down syndrome and Alzheimer\u2019s disease","volume":"33","author":"Alldred","year":"2019","journal-title":"FASEB J."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.3390\/ijms9112091","article-title":"Terminal continuation (TC) RNA amplification enables expression profiling using minute RNA input obtained from mouse brain","volume":"9","author":"Alldred","year":"2008","journal-title":"Int. J. Mol. Sci."},{"key":"B6","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/j.nbd.2011.10.022","article-title":"Microarray analysis of CA1 pyramidal neurons in a mouse model of tauopathy reveals progressive synaptic dysfunction","volume":"45","author":"Alldred","year":"2012","journal-title":"Neurobiol. Dis."},{"key":"B7","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/cne.23663","article-title":"Expression profile analysis of vulnerable CA1 pyramidal neurons in young-middle-aged Ts65Dn mice","volume":"523","author":"Alldred","year":"","journal-title":"J. Comp. Neurol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"2983","DOI":"10.1007\/s00429-014-0839-0","article-title":"Expression profile analysis of hippocampal CA1 pyramidal neurons in aged Ts65Dn mice, a model of down syndrome (DS) and Alzheimer\u2019s disease (AD)","volume":"220","author":"Alldred","year":"","journal-title":"Brain Struct. Funct."},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s12035-021-02453-3","article-title":"Profiling basal forebrain cholinergic neurons reveals a molecular basis for vulnerability within the ts65dn model of down syndrome and Alzheimer\u2019s disease","author":"Alldred","year":"2021","journal-title":"Mol. Neurobiol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/j.jalz.2015.07.490","article-title":"The pattern of amyloid accumulation in the brains of adults with down syndrome","volume":"12","author":"Annus","year":"2016","journal-title":"Alzheimers Dement."},{"key":"B11","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.brainres.2007.10.045","article-title":"Mitochondrial dysfunction in mouse trisomy 16 brain","volume":"1188","author":"Bambrick","year":"2008","journal-title":"Brain Res."},{"key":"B12","doi-asserted-by":"publisher","first-page":"101871","DOI":"10.1016\/j.redox.2021.101871","article-title":"Down syndrome is an oxidative phosphorylation disorder","volume":"41","author":"Bayona-Bafaluy","year":"2021","journal-title":"Redox Biol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1017\/S0033291708004054","article-title":"Alzheimer\u2019s disease and Down\u2019s syndrome: an in vivo MRI study","volume":"39","author":"Beacher","year":"2009","journal-title":"Psychol. Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1002\/cne.21895","article-title":"Excitatory-inhibitory relationship in the fascia dentata in the Ts65Dn mouse model of down syndrome","volume":"512","author":"Belichenko","year":"2009","journal-title":"J. Comp. Neurol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1002\/cne.20337","article-title":"Synaptic structural abnormalities in the Ts65Dn mouse model of down Syndrome","volume":"480","author":"Belichenko","year":"2004","journal-title":"J. Comp. Neurol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1093\/eurpub\/ckl103","article-title":"The four ages of down syndrome","volume":"17","author":"Bittles","year":"2007","journal-title":"Eur. J. Public Health"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2467","DOI":"10.1080\/15548627.2016.1239003","article-title":"Autophagy flux in CA1 neurons of Alzheimer hippocampus: increased induction overburdens failing lysosomes to propel neuritic dystrophy","volume":"12","author":"Bordi","year":"2016","journal-title":"Autophagy"},{"key":"B18","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41419-019-1752-5","article-title":"mTOR hyperactivation in down syndrome underlies deficits in autophagy induction, autophagosome formation and mitophagy","volume":"10","author":"Bordi","year":"2019","journal-title":"Cell Death Dis."},{"key":"B19","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1016\/j.bbrc.2016.09.088","article-title":"Emerging pathways driving early synaptic pathology in Alzheimer\u2019s disease","volume":"483","author":"Briggs","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"B20","doi-asserted-by":"publisher","first-page":"e30","DOI":"10.1212\/WNL.0000000000008696","article-title":"Plasma tau correlates with basal forebrain atrophy rates in people at risk for Alzheimer disease","volume":"94","author":"Cavedo","year":"2020","journal-title":"Neurology"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1017\/S143192762002437X","article-title":"Combined microscopic and metabolomic approach to characterize the skeletal muscle fiber of the Ts65Dn mouse, a model of down syndrome","volume":"26","author":"Cisterna","year":"2020","journal-title":"Microsc. Microanal."},{"key":"B22","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1111\/j.1471-4159.2006.03769.x","article-title":"Choline acetyltransferase activity at different ages in brain of Ts65Dn mice, an animal model for down\u2019s syndrome and related neurodegenerative diseases","volume":"97","author":"Contestabile","year":"2006","journal-title":"J. Neurochem."},{"key":"B23","doi-asserted-by":"publisher","first-page":"10439","DOI":"10.1073\/pnas.181219298","article-title":"Failed retrograde transport of NGF in a mouse model of down\u2019s syndrome: reversal of cholinergic neurodegenerative phenotypes following NGF infusion","volume":"98","author":"Cooper","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"B24","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1038\/nrneurol.2012.40","article-title":"Alzheimer disease: treatment of Alzheimer disease in down syndrome","volume":"8","author":"Costa","year":"2012","journal-title":"Nat. Rev. Neurol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/0166-2236(88)90075-6","article-title":"down syndrome, Alzheimer\u2019s disease and the trisomy16 mouse","volume":"11","author":"Coyle","year":"1988","journal-title":"Trends Neurosci."},{"key":"B26","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/0361-9230(86)90074-2","article-title":"The neurobiologic consequences of down syndrome","volume":"16","author":"Coyle","year":"1986","journal-title":"Brain Res. Bull."},{"key":"B27","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1097\/WAD.0000000000000132","article-title":"Cognitive profiles on the severe impairment battery are similar in Alzheimer disease and Down syndrome with dementia","volume":"30","author":"Dick","year":"2016","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"B28","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1007\/s00335-011-9356-0","article-title":"Identification of the translocation breakpoints in the Ts65Dn and Ts1Cje mouse lines: relevance for modeling down syndrome","volume":"22","author":"Duchon","year":"2011","journal-title":"Mamm. Genome"},{"key":"B29","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1093\/brain\/awaa012","article-title":"Basal forebrain volume reliably predicts the cortical spread of Alzheimer\u2019s degeneration","volume":"143","author":"Fern\u00e1ndez-Cabello","year":"2020","journal-title":"Brain"},{"key":"B30","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jalz.2015.12.003","article-title":"Why has therapy development for dementia failed in the last two decades?","volume":"12","author":"Gauthier","year":"2016","journal-title":"Alzheimers Dement."},{"key":"B31","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.biopsych.2010.05.030","article-title":"Microarray analysis of hippocampal CA1 neurons implicates early endosomal dysfunction during Alzheimer\u2019s disease progression","volume":"68","author":"Ginsberg","year":"2010","journal-title":"Biol. Psychiatry."},{"key":"B32","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1006\/exnr.1999.7289","article-title":"Loss of cholinergic phenotype in basal forebrain coincides with cognitive decline in a mouse model of down\u2019s syndrome","volume":"161","author":"Granholm","year":"2000","journal-title":"Exp. Neurol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1016\/j.neurobiolaging.2012.10.018","article-title":"Longitudinal measures of cholinergic forebrain atrophy in the transition from healthy aging to Alzheimer\u2019s disease","volume":"34","author":"Grothe","year":"2013","journal-title":"Neurobiol. Aging"},{"key":"B34","doi-asserted-by":"publisher","first-page":"8940","DOI":"10.1523\/JNEUROSCI.0026-12.2012","article-title":"Oxidative phosphorylation, not glycolysis, powers presynaptic and postsynaptic mechanisms underlying brain information processing","volume":"32","author":"Hall","year":"2012","journal-title":"J. Neurosci."},{"key":"B35","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.jalz.2014.10.007","article-title":"down syndrome and Alzheimer\u2019s disease: common pathways, common goals","volume":"11","author":"Hartley","year":"2015","journal-title":"Alzheimers Dement."},{"key":"B36","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.cmet.2012.12.005","article-title":"Adaptive downregulation of mitochondrial function in down syndrome","volume":"17","author":"Helguera","year":"2013","journal-title":"Cell Metab."},{"key":"B37","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1001\/archinte.163.6.705","article-title":"Mortality and cancer incidence among individuals with down syndrome","volume":"163","author":"Hill","year":"2003","journal-title":"Arch. Intern. Med."},{"key":"B38","doi-asserted-by":"publisher","first-page":"13333","DOI":"10.1073\/pnas.93.23.13333","article-title":"Developmental abnormalities and age-related neurodegeneration in a mouse model of down syndrome","volume":"93","author":"Holtzman","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"B39","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/s0166-4328(02)00275-9","article-title":"Behavioral comparison of 4 and 6 month-old Ts65Dn mice: Age-related impairments in working and reference memory","volume":"138","author":"Hunter","year":"","journal-title":"Behav. Brain Res."},{"key":"B40","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/s0168-0102(03)00005-1","article-title":"Regional alterations in amyloid precursor protein and nerve growth factor across age in a mouse model of down\u2019s syndrome","volume":"45","author":"Hunter","year":"","journal-title":"Neurosci. Res."},{"key":"B41","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1093\/brain\/awt372","article-title":"Nerve growth factor metabolic dysfunction in Down\u2019s syndrome brains","volume":"137","author":"Iulita","year":"2014","journal-title":"Brain"},{"key":"B42","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s10020-018-0004-y","article-title":"Mitochondrial dysfunction in down syndrome: molecular mechanisms and therapeutic targets","volume":"24","author":"Izzo","year":"2018","journal-title":"Mol. Med."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1073\/pnas.0908953107","article-title":"Alzheimer\u2019s-related endosome dysfunction in down syndrome is Abeta-independent but requires APP and is reversed by BACE-1 inhibition","volume":"107","author":"Jiang","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1002\/cne.23492","article-title":"Maternal choline supplementation differentially alters the basal forebrain cholinergic system of young-adult Ts65Dn and disomic mice","volume":"522","author":"Kelley","year":"","journal-title":"J. Comp. Neurol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/bpa.12073","article-title":"Sex differences in the cholinergic basal forebrain in the Ts65Dn mouse model of down syndrome and Alzheimer\u2019s disease","volume":"24","author":"Kelley","year":"","journal-title":"Brain Pathol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"2741","DOI":"10.1016\/s0024-3205(01)01074-8","article-title":"The reduction of NADH ubiquinone oxidoreductase 24- and 75-kDa subunits in brains of patients with down syndrome and Alzheimer\u2019s disease","volume":"68","author":"Kim","year":"2001","journal-title":"Life Sci."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1007\/pl00000661","article-title":"Decreased levels of complex III core protein 1 and complex V beta chain in brains from patients with Alzheimer\u2019s disease and down syndrome","volume":"57","author":"Kim","year":"2000","journal-title":"Cell. Mol. Life Sci."},{"key":"B48","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.freeradbiomed.2021.01.042","article-title":"Insulin resistance, oxidative stress and mitochondrial defects in Ts65dn mice brain: A harmful synergistic path in down syndrome","volume":"165","author":"Lanzillotta","year":"2021","journal-title":"Free Radic. Biol. Med."},{"key":"B49","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/B978-0-444-54299-1.00006-6","article-title":"Neurological phenotypes for down syndrome across the life span","volume":"197","author":"Lott","year":"2012","journal-title":"Prog. Brain Res."},{"key":"B50","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/S1474-4422(10)70112-5","article-title":"Cognitive deficits and associated neurological complications in individuals with down\u2019s syndrome","volume":"9","author":"Lott","year":"2010","journal-title":"Lancet Neurol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1002\/bdr2.1589","article-title":"National population-based estimates for major birth defects, 2010\u20132014","volume":"111","author":"Mai","year":"2019","journal-title":"Birth Defects Res."},{"key":"B52","doi-asserted-by":"publisher","first-page":"4318","DOI":"10.1002\/1873-3468.12461","article-title":"Choline and dimethylglycine produce superoxide\/hydrogen peroxide from the electron transport chain in liver mitochondria","volume":"590","author":"Mailloux","year":"2016","journal-title":"FEBS Lett."},{"key":"B53","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1111\/j.1365-2990.1984.tb00351.x","article-title":"Alzheimer\u2019s presenile dementia, senile dementia of Alzheimer type and down\u2019s syndrome in middle age form an age related continuum of pathological changes","volume":"10","author":"Mann","year":"1984","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.neuron.2008.10.010","article-title":"Mitochondria in neuroplasticity and neurological disorders","volume":"60","author":"Mattson","year":"2008","journal-title":"Neuron"},{"key":"B55","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1758-907X-2-2","article-title":"Experimental design, preprocessing, normalization and differential expression analysis of small RNA sequencing experiments","volume":"2","author":"McCormick","year":"2011","journal-title":"Silence"},{"key":"B56","volume-title":"Generalized, Linear and Mixed Models.","author":"McCulloch","year":"2011"},{"key":"B57","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1002\/cne.902140206","article-title":"Cholinergic innervation of cortex by the basal forebrain: cytochemistry and cortical connections of the septal area, diagonal band nuclei, nucleus basalis (substantia innominata) and hypothalamus in the rhesus monkey","volume":"214","author":"Mesulam","year":"1983","journal-title":"J. Comp. Neurol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"3134","DOI":"10.3390\/ijms21093134","article-title":"Targeting mitochondrial network architecture in down syndrome and aging","volume":"21","author":"Mollo","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"B59","doi-asserted-by":"publisher","first-page":"606","DOI":"10.3389\/fgene.2019.00606","article-title":"Pioglitazone improves mitochondrial organization and bioenergetics in down syndrome cells","volume":"10","author":"Mollo","year":"2019","journal-title":"Front. Genet."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1023\/a:1020952704398","article-title":"Gene expression profiles of cholinergic nucleus basalis neurons in Alzheimer\u2019s disease","volume":"27","author":"Mufson","year":"2002","journal-title":"Neurochem. Res."},{"key":"B61","doi-asserted-by":"publisher","first-page":"533","DOI":"10.3389\/fnins.2019.00533","article-title":"Nerve growth factor pathobiology during the progression of Alzheimer\u2019s disease","volume":"13","author":"Mufson","year":"2019","journal-title":"Front. Neurosci."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1586\/14737175.8.11.1703","article-title":"Cholinergic system during the progression of Alzheimer\u2019s disease: therapeutic implications","volume":"8","author":"Mufson","year":"2008","journal-title":"Expert Rev. Neurother."},{"key":"B63","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/s0891-0618(03)00068-1","article-title":"Human cholinergic basal forebrain: chemoanatomy and neurologic dysfunction","volume":"26","author":"Mufson","year":"2003","journal-title":"J. Chem. Neuroanat."},{"key":"B64","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.bbr.2016.05.030","article-title":"Molecular and cellular pathophysiology of preclinical Alzheimer\u2019s disease","volume":"311","author":"Mufson","year":"2016","journal-title":"Behav. Brain Res."},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1038\/NMETH.F.353","article-title":"The simple Western\u2122: a gel-free, blot-free, hands-free Western blotting reinvention","volume":"8","author":"Nguyen","year":"2011","journal-title":"Nature Methods"},{"key":"B66","volume-title":"The Mouse Brain in Stereotaxic Coordinates. Second Edition.","author":"Paxinos","year":"2001"},{"key":"B67","doi-asserted-by":"publisher","first-page":"4337","DOI":"10.1007\/s00429-015-1164-y","article-title":"Attentional function and basal forebrain cholinergic neuron morphology during aging in the Ts65Dn mouse model of down syndrome","volume":"221","author":"Powers","year":"2016","journal-title":"Brain Struct. Funct."},{"key":"B68","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1080\/01621459.1959.10501526","article-title":"Remarks on zeros and ties in the wilcoxon signed rank procedures","volume":"54","author":"Pratt","year":"1959","journal-title":"J. Stat. Am. Assoc."},{"key":"B69","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/j.jpeds.2013.06.013","article-title":"Current estimate of Down Syndrome population prevalence in the United States","volume":"163","author":"Presson","year":"2013","journal-title":"J. Pediatr."},{"key":"B70","doi-asserted-by":"publisher","first-page":"584071","DOI":"10.1155\/2012\/584071","article-title":"Mouse models of down syndrome as a tool to unravel the causes of mental disabilities","volume":"2012","author":"Rueda","year":"2012","journal-title":"Neural Plast."},{"key":"B71","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1016\/j.conb.2012.05.002","article-title":"Cognitive and pharmacological insights from the Ts65Dn mouse model of down syndrome","volume":"22","author":"Ruparelia","year":"2012","journal-title":"Curr. Opin. Neurobiol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1046\/j.1471-4159.2000.741185.x","article-title":"Reduction in TrkA-immunoreactive neurons is not associated with an overexpression of galaninergic fibers within the nucleus basalis in down\u2019s syndrome","volume":"74","author":"Sendera","year":"2000","journal-title":"J. Neurochem."},{"key":"B73","doi-asserted-by":"publisher","first-page":"2752","DOI":"10.1093\/hmg\/ddl211","article-title":"Mitochondrial dysfunction and tau hyperphosphorylation in Ts1Cje, a mouse model for down syndrome","volume":"15","author":"Shukkur","year":"2006","journal-title":"Hum. Mol. Genet."},{"key":"B74","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1111\/j.1365-2788.2007.01013.x","article-title":"Hospitalizations of infants and young children with down syndrome: evidence from inpatient person-records from a statewide administrative database","volume":"51","author":"So","year":"2007","journal-title":"J. Intellect. Disabil. Res."},{"key":"B75","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1038\/s41576-019-0150-2","article-title":"RNA sequencing: the teenage years","volume":"20","author":"Stark","year":"2019","journal-title":"Nat. Rev. Genet."},{"key":"B76","doi-asserted-by":"publisher","first-page":"97","DOI":"10.2174\/1567205012666150921100311","article-title":"Maternal choline supplementation: a potential prenatal treatment for down syndrome and Alzheimer\u2019s disease","volume":"13","author":"Strupp","year":"2016","journal-title":"Curr. Alzheimer Res."},{"key":"B77","doi-asserted-by":"publisher","first-page":"e1301","DOI":"10.1212\/WNL.0000000000010192","article-title":"Neuropathologic features associated with basal forebrain atrophy in Alzheimer disease","volume":"95","author":"Teipel","year":"2020","journal-title":"Neurology"},{"key":"B78","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/j.neubiorev.2016.10.023","article-title":"Plant polyphenols as natural drugs for the management of down syndrome and related disorders","volume":"71","author":"Vacca","year":"2016","journal-title":"Neurosci. Biobehav. Rev."},{"key":"B80","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.neubiorev.2014.01.012","article-title":"Mitochondrial dysfunction as a central actor in intellectual disability-related diseases: an overview of down syndrome, autism, Fragile X and Rett syndrome","volume":"46","author":"Valenti","year":"2014","journal-title":"Neurosci. Biobehav. Rev."},{"key":"B81","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1016\/j.bbadis.2016.03.003","article-title":"The polyphenols resveratrol and epigallocatechin-3-gallate restore the severe impairment of mitochondria in hippocampal progenitor cells from a down syndrome mouse model","volume":"1862","author":"Valenti","year":"2016","journal-title":"Biochim. Biophys. Acta"},{"key":"B79","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.freeradbiomed.2017.08.014","article-title":"Mitochondria as pharmacological targets in down syndrome","volume":"114","author":"Valenti","year":"2018","journal-title":"Free Radic. Biol. Med."},{"key":"B82","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1093\/jee\/39.2.269","article-title":"Individual comparisons of grouped data by ranking methods","volume":"39","author":"Wilcoxon","year":"1946","journal-title":"J. Econ. Entomol."},{"key":"B83","doi-asserted-by":"publisher","first-page":"4312","DOI":"10.1096\/fj.14-251736","article-title":"Maternal choline supplementation programs greater activity of the phosphatidylethanolamine N-methyltransferase (PEMT) pathway in adult Ts65Dn trisomic mice","volume":"28","author":"Yan","year":"2014","journal-title":"FASEB J."},{"key":"B84","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1016\/s0140-6736(80)92137-6","article-title":"Alzheimer-like cholinergic deficiency in down syndrome","volume":"2","author":"Yates","year":"1980","journal-title":"Lancet"},{"key":"B85","doi-asserted-by":"publisher","first-page":"97","DOI":"10.3390\/biomedicines7040097","article-title":"Reasons for failed trials of disease-modifying treatments for Alzheimer disease and their contribution in recent research","volume":"7","author":"Yiannopoulou","year":"2019","journal-title":"Biomedicines"}],"container-title":["Frontiers in Aging Neuroscience"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnagi.2021.707950\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,19]],"date-time":"2021-08-19T11:29:57Z","timestamp":1629372597000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnagi.2021.707950\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,19]]},"references-count":85,"alternative-id":["10.3389\/fnagi.2021.707950"],"URL":"https:\/\/doi.org\/10.3389\/fnagi.2021.707950","relation":{},"ISSN":["1663-4365"],"issn-type":[{"value":"1663-4365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,19]]},"article-number":"707950"}}